Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2475-2480

  Bradley, Jeffrey D ^a   Bae, Kyounghwa ^a   Graham, Mary V ^a   Byhardt, Roger ^a   Govindan, Ramaswamy ^a   Fowler, Jack ^a   Purdy, James A ^a   Michalski, Jeff M ^a   Gore, Elizabeth ^a   Choy, Hak ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLERGY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING DISORDER; HEART ARRHYTHMIA; HEMOPTYSIS; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION HAZARD; REPRODUCTIVE TOXICITY; SKIN TOXICITY; SURVIVAL TIME; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952488310     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.1205     Document Type: Article

References (20)

1. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung: Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744-2753, 1980 (Pubitemid 10063330)
2. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
3. Bradley J, Graham M, Swann S, et al: Phase I results of RTOG L-0117: A phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. J Clin Oncol 23:636s, 2005 (suppl: abstr 7063)
4. Curran W, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
5. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
6. Kaplan E, Meier P: Nonparameteric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. Blumenschein G, Moughan J, Curran W: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial. J Clin Oncol 25:392s, 2007 (suppl; abstr 7531)
8. Movsas B, Scott C, Langer C, et al: Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy & hyperfractionated radiation (chemo/HFxRT): Radiation Therapy Oncology Group (RTOG) 98-01. Proc Am Soc Clin Oncol 22:636, 2003 (abstr 2559)
9. Bradley J, Graham MV, Winter K, et al: Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318-328, 2005 (Pubitemid 40164423)
10. Schild SE, McGinnis WL, Graham D, et al: Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 65:1106-1111, 2006
11. Socinski MA, Blackstock AW, Bogart JA, et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
12. Rosenman JG, Halle JS, Socinski MA, et al: High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348-356, 2002 (Pubitemid 35286797)
13. Socinski MA, Kies M, Schell MJ, et al: Duration of therapy in stage IIIB/IV non-small cell lung cancer (NSCLC): A multi-institutional phase III trial. Proc Am Soc Clin Oncol 20:309a, 2001(abstr 1232)
14. Socinski MA, Morris DE, Halle JS, et al: Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22:4341-4350, 2004 (Pubitemid 41185154)
15. Stinchcombe TE, Lee CB, Moore DT, et al: Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 3:1279-1285, 2008
16. Lee CB, Stinchcombe TE, Moore DT, et al: Late complications of high-dose (>/= 66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:74-79, 2009
17. Vokes EE, Herndon JE 2nd, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007 (Pubitemid 46797950)
18. Morgensztern D, Goodgame B, Baggstrom M, et al: The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol 3:135-139, 2008 (Pubitemid 351323187)
19. Hicks RJ, Kalff V, MacManus MP, et al: (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596-1604, 2001 (Pubitemid 33131317)
20. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000 (Pubitemid 30490393)